Free Trial
CVE:AQS

Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis

C$0.03
-0.01 (-14.29%)
(As of 07/12/2024)
Today's Range
C$0.03
C$0.04
50-Day Range
C$0.02
C$0.04
52-Week Range
C$0.01
C$0.06
Volume
371,428 shs
Average Volume
201,752 shs
Market Capitalization
C$3.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AQS stock logo

About Aequus Pharmaceuticals Stock (CVE:AQS)

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

AQS Stock Price History

AQS Stock News Headlines

Aequus Pharmaceuticals (CVE:AQS) Shares Down 28.6%
Catalyst Could Trigger 10,000% Crypto Gains
Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look:
AQS:CA Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc AQS
Aequus Pharmaceuticals reports Q3 results
Catalyst Could Trigger 10,000% Crypto Gains
Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look:
Closing Bell: Aequus Pharmaceuticals Inc flat on Friday (AQS)
Aequus Announces Zimed PF Now Available in Canada
See More Headlines
Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/29/2024
Today
7/17/2024
Next Earnings (Estimated)
9/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
C$-2,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.17 million
Cash Flow
C$0.01 per share
Book Value
C($0.03) per share

Miscellaneous

Free Float
N/A
Market Cap
C$3.98 million
Optionable
Not Optionable
Beta
0.17
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Douglas Glen Janzen (Age 55)
    Chairman, CEO & President
    Comp: $206.25k
  • Ms. Ann Fehr CGA (Age 55)
    CPA, CFO & Corporate Secretary
    Comp: $136.13k
  • Mr. Grant Larsen
    Chief Commercial Officer

AQS Stock Analysis - Frequently Asked Questions

How have AQS shares performed this year?

Aequus Pharmaceuticals' stock was trading at C$0.03 at the beginning of 2024. Since then, AQS shares have increased by 20.0% and is now trading at C$0.03.
View the best growth stocks for 2024 here
.

How were Aequus Pharmaceuticals' earnings last quarter?

Aequus Pharmaceuticals Inc. (CVE:AQS) issued its quarterly earnings results on Monday, April, 29th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.05 million for the quarter.

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle (CCI), Charlotte's Web (CWBHF) and (FIRE.V) (FIRE).

This page (CVE:AQS) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners